iRhythm Q3 loss widens to $29.9M as revenue rises
The raised 2026 outlook includes approximately $16 million of expected VitalConnect revenue, alongside a newly closed $300 million senior secured revolving credit facility.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
iRhythm Holdings, Inc. reported third-quarter 2026 revenue of $221.6 million, up 14.9% from $192.9 million a year earlier. Gross margin was 74.2%, up 310 basis points. Adjusted EBITDA was $51.2 million and adjusted EBITDA margin was 23.1%, up $29.6 million and 1,190 basis points year over year, respectively. GAAP net loss widened to $29.9 million from $5.2 million; operating expenses included $49.8 million in litigation settlements.
iRhythm raised fiscal 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%. The outlook includes approximately $16 million of expected VitalConnect revenue from the October 5, 2026 acquisition close through year-end. iRhythm closed a new $300 million senior secured revolving credit facility on November 3, 2026. Unrestricted cash, cash equivalents and marketable securities totaled $560.7 million as of September 30, 2026.
iRhythm submitted FDA 510(k) applications for pediatric use of Zio Monitor. Operating cash flow was $4.4 million in the quarter, versus $34.9 million a year earlier.
3 points · 0 major0 major · 2 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointRevenue rose 14.9% year over year to $221.6 million.
- Moderate pointAdjusted EBITDA increased $29.6 million year over year to $51.2 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.VitalConnect acquisition closed October 5, 2026; expected 2026 revenue contribution: approximately $16 million.
Negative
- Moderate pointGAAP net loss widened $24.6 million year over year to $29.9 million.
- Moderate pointOperating cash flow was $4.4 million, versus $34.9 million in Q3 2025.
Filing Explained
The third-quarter statements report operating cash flow of
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Revenue: $221.6 million
Gross margin: 74.2%
GAAP net loss: $29.9 million loss
+5 more
8 metrics
Revenue
$221.6 million
Three months ended September 30, 2026; $192.9 million in Q3 2025; up 14.9%.
Gross margin
74.2%
Third quarter 2026; up 310 basis points year over year.
GAAP net loss
$29.9 million loss
Third quarter 2026; $5.2 million loss in Q3 2025; net loss increased by $24.6 million.
Adjusted EBITDA
$51.2 million
Third quarter 2026; $21.6 million in Q3 2025; increased by $29.6 million.
Operating cash flow
$4.4 million
Third quarter 2026; $34.9 million in Q3 2025.
Fiscal 2026 revenue guidance
$890 million to $895 million
Raised guidance; includes approximately $16 million of expected VitalConnect revenue from the October 5, 2026 close through year-end.
Fiscal 2026 adjusted EBITDA margin guidance
15.5% to 16.0%
Raised guidance; inclusive of VitalConnect.
Unrestricted cash, cash equivalents, and marketable securities
$560.7 million
As of September 30, 2026.
Key Terms
Adjusted EBITDA, Adjusted EBITDA margin, Mobile cardiac telemetry, 510(k), +1 more
5 terms
Adjusted EBITDA financial
"Adjusted EBITDA is defined as net income (loss) before income tax provision"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Adjusted EBITDA margin financial
"adjusted EBITDA margin guidance to 15.5% to 16.0%"
Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.
Mobile cardiac telemetry technical
"immediate FDA-cleared mobile cardiac telemetry offering"
A wearable system that continuously records a person’s heart rhythm and sends that data in real time to clinicians or monitoring centers for immediate analysis and alerting. Think of it as a live security camera for the heart that can catch irregular beats or dangerous events that short clinic tests might miss. Investors care because it can drive recurring service revenue, affect reimbursement and adoption trends, and reduce costly hospital visits by enabling earlier detection and remote care.
510(k) regulatory
"Submitted FDA 510(k) applications for pediatric use"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
Business transformation costs financial
"Business transformation costs include costs associated with professional services"
Business transformation costs are one-time or short-term expenses a company incurs to change how it operates—such as restructuring, new technology, layoffs, or retraining—so it can compete better in the future. Investors care because these costs reduce near-term profits and cash flow but may improve long-term efficiency and competitiveness; think of it as paying for a renovation that temporarily disrupts a store but aims to increase future sales and lower running costs.
Earnings Snapshot
Revenue: $221.6 million · Guidance included
Third quarter 2026
Revenue
$221.6 million
Up 14.9% year over year
Gross margin
74.2%
Up 310 basis points year over year
GAAP net loss
$29.9 million loss
Net loss increased by $24.6 million year over year
Adjusted EBITDA
$51.2 million
Increased by $29.6 million year over year
Guidance
Fiscal 2026 revenue of $890 million to $895 million and adjusted EBITDA margin of 15.5% to 16.0%, inclusive of VitalConnect.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were IRTC's third-quarter 2026 revenue and net loss?
iRhythm reported Q3 2026 revenue of $221.6 million, up 14.9% from $192.9 million in Q3 2025. GAAP net loss was $29.9 million, compared with $5.2 million in Q3 2025.
What is IRTC's fiscal 2026 revenue guidance?
iRhythm raised 2026 revenue guidance to $890 million to $895 million. The range includes approximately $16 million in expected VitalConnect revenue from the October 5, 2026 acquisition close through year-end.
What adjusted EBITDA did IRTC report for Q3 2026?
iRhythm reported adjusted EBITDA of $51.2 million for Q3 2026, compared with $21.6 million in Q3 2025. Adjusted EBITDA margin was 23.1%, up 1,190 basis points year over year. The company identifies adjusted EBITDA as a non-GAAP financial measure.
What new credit facility did IRTC close?
iRhythm closed a new $300 million senior secured revolving credit facility on November 3, 2026.
What pediatric-use application did IRTC submit to the FDA?
iRhythm submitted FDA 510(k) applications for pediatric use with its Zio Monitor long-term continuous monitoring business.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 5, 2026
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||||||||||||||||||||
(Address of principal executive office) (Zip Code)
(415 ) 632-5700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 5, 2026, the Company issued a press release regarding its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits. | ||||||||||||||||
| Exhibit No. | Description | |||||||||||||||||||||||||
| 99.1 | Press release issued by iRhythm Holdings, Inc., dated as of November 5, 2026 related to financial results. | |||||||||||||||||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IRHYTHM HOLDINGS, INC. | |||||||||||||||||||||||||||||||||||
Date: November 5, 2026 | By: | /s/ Daniel Wilson | |||||||||||||||||||||||||||||||||
| Daniel Wilson | |||||||||||||||||||||||||||||||||||
| Chief Financial Officer | |||||||||||||||||||||||||||||||||||
Exhibit 99.1
iRhythm Holdings Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, November 5, 2026 -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.
Third Quarter 2026 Financial Highlights
•Revenue of $221.6 million, a 14.9% increase compared to third quarter 2025
•Gross margin of 74.2%, a 310-basis point increase compared to third quarter 2025
•GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared to third quarter 2025
•Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%, respectively, a $29.6 million and 1,190-basis point improvement, respectively, compared to third quarter 2025
•Unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026
•Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%
Recent Operational Highlights
•Delivered another strong quarter, driven by healthy volume-led revenue growth of Zio Monitor and robust margin expansion, with broad-based momentum across cardiology, primary care, innovative channels and international markets
•Completed the acquisition of VitalConnect on October 5, 2026, broadening our cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering, advancing our multi-vitals strategy, and expanding our addressable market across the continuum of care
•Published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT1), Zio Long-Term Continuous Monitoring (EXCALIBUR2), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT3 in over 1.7 million total patients
•Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long-term continuous monitoring business
•Closed a new $300 million senior secured revolving credit facility on November 3, 2026, providing additional liquidity to support our long-term growth objectives
“Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “With the acquisition of VitalConnect now closed, we are encouraged by the early opportunities we see to broaden our capabilities and serve more patients within the ambulatory cardiac monitoring market and across the continuum of care. With an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be able to offer the marketplace a best-in-class MCT portfolio of options. We remain focused on advancing innovation, expanding access to Zio, and investing in the growth initiatives that we believe will create durable value for patients, clinicians, and stockholders.”
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.
Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from $137.1 million during the same period in 2025, while gross margin was 74.2%, a 310-basis point improvement compared to the third quarter of 2025. The increase in gross profit was primarily due to increased volume of Zio services, as well as a one-time benefit from tariff refunds of approximately $3.1 million. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, a tariff refund one-time benefit, and disciplined execution.
Exhibit 99.1
Operating expenses for the third quarter of 2026 were $197.0 million, compared to $145.6 million for the same period in 2025. Adjusted operating expenses for the third quarter of 2026 were $138.6 million, compared to $141.4 million during the same period in 2025. The decrease in adjusted operating expenses, period over period, reflects a disciplined approach to investment, as we funded key growth initiatives while thoughtfully managing costs across the broader organization.
GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss per diluted share of $0.16, for the same period in 2025. Adjusted net income for the third quarter of 2026 was $27.8 million, or net income per diluted share of $0.82, compared with an adjusted net loss of $2.0 million, or net loss per diluted share of $0.06, for the same period in 2025. The improvement was primarily driven by our revenue growth and operating leverage achieved through implementation of efficiency initiatives.
Unrestricted cash, cash equivalents, and marketable securities were $560.7 million as of September 30, 2026.
2026 Annual Guidance
For the full year 2026, iRhythm expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5, 2026 acquisition close through year-end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%, inclusive of VitalConnect. iRhythm’s guidance reflects continued volume-led growth and operating leverage while maintaining disciplined investment in innovation and market expansion.
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per diluted share, adjusted operating expenses and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures may be helpful to investors. However, non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our disclosure of non-GAAP financial measures as a tool for comparison. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA margin estimates is not available without unreasonable effort.
Adjusted EBITDA is defined as net income (loss) before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted for stock-based compensation expense, changes in fair value of strategic investments, impairment charges, business transformation costs, certain intellectual property litigation expenses, certain litigation settlements (net of expected insurance recoveries), costs related to the cybersecurity incident (net of expected insurance recoveries), and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.
Exhibit 99.1
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding our financial guidance, volume growth and margin expansion, market opportunity, ability to penetrate the market, expansion into new health programs, international market expansion, anticipated productivity and quality improvements, anticipated demand for our products and services and our expectations for growth, and statements regarding the anticipated benefits of the VitalConnect acquisition, including our ability to broaden our capabilities, advance our multi-vitals strategy, expand our addressable market and serve more patients across the continuum of care, our ability to create durable, long-term value for patients, clinicians and stockholders; and the anticipated benefits of our revolving credit facility. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: intense competition in the markets we compete in; fluctuations in our operating results; our ability to successfully integrate any acquisitions or strategic investments; risks associated with managing our growth; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; distribution and supply chain disruptions and cost increases; new product and service introductions and the market acceptance of those products and services; expected pricing environment; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy; and future business decisions made by us and our competitors. Additional risks are described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q expected to be filed on or about November 5, 2026. These forward-looking statements speak only as of the date of this press release and should not be unduly relied upon. iRhythm undertakes no obligation to update them except as required by law.
Investor Contact
Francis Pruell
investors@irhythmtech.com
Media Contact
Kassandra Perry
mediarelations@irhythmtech.com
1.Russo P, Strom J, Nathan R, Song Y, Shokoohi M, Passman R, Reynolds M, Mittal S. Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT-ALERT study. American Heart Journal. 2026 Aug 28. doi: 10.1016/j.ahj.2026.10759
2.Mittal S, Reynolds MR, Hughes A, Buysman EK, Hendrickson EM, Boyle K, Wright B, Ashburner JM, Turakhia M, Passman RS. Comparative Clinical Outcomes Across Ambulatory Cardiac Monitoring Modalities. Clin Cardiology. 2026 Oct;49(10):e70500. doi:10.1002/clc.70500
3.Knight BP, Pinkerton R, Ellis J, Ashburner JM, Wazni OM, Passman RS, Turakhia MP, Mittal M. Real-world performance and diagnostic yield gains of a next-generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor. Heart Rhythm O2. October 9, 2026. https://www.heartrhythmopen.com/article/S2666-5018(26)00597-0/fulltext
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except par value)
| (unaudited) | September 30, 2026 | December 31, 2025 | |||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 394,718 | $ | 236,012 | |||||||
| Restricted cash | 10,000 | — | |||||||||
| Marketable securities | 166,001 | 347,751 | |||||||||
| Accounts receivable, net | 81,126 | 75,706 | |||||||||
| Inventory | 23,222 | 21,634 | |||||||||
| Prepaid expenses and other current assets | 55,143 | 21,662 | |||||||||
| Total current assets | 730,210 | 702,765 | |||||||||
| Property and equipment, net | 176,938 | 151,599 | |||||||||
| Operating lease right-of-use assets | 37,670 | 41,827 | |||||||||
Restricted cash | 8,358 | 8,358 | |||||||||
| Goodwill | 862 | 862 | |||||||||
| Long-term strategic investments | 74,514 | 69,913 | |||||||||
| Other assets | 62,889 | 44,718 | |||||||||
| Total assets | $ | 1,091,441 | $ | 1,020,042 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 15,395 | $ | 2,256 | |||||||
| Accrued liabilities | 167,630 | 128,747 | |||||||||
| Deferred revenue | 4,668 | 4,201 | |||||||||
| Operating lease liabilities, current portion | 17,039 | 16,686 | |||||||||
| Total current liabilities | 204,732 | 151,890 | |||||||||
| Long-term senior convertible notes | 651,858 | 649,504 | |||||||||
| Other noncurrent liabilities | 908 | 908 | |||||||||
| Operating lease liabilities, noncurrent portion | 56,837 | 64,994 | |||||||||
| Total liabilities | 914,335 | 867,296 | |||||||||
| Stockholders’ equity: | |||||||||||
Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at September 30, 2026 and December 31, 2025 | — | — | |||||||||
Common stock, $0.001 par value – 100,000 shares authorized; 33,414 shares issued and 33,185 shares outstanding at September 30, 2026, and 32,526 shares issued and 32,297 shares outstanding at December 31, 2025 | 33 | 32 | |||||||||
| Additional paid-in capital | 1,049,900 | 980,757 | |||||||||
| Accumulated other comprehensive (loss) income | (216) | 403 | |||||||||
| Accumulated deficit | (847,611) | (803,446) | |||||||||
Treasury stock, at cost; 229 shares at September 30, 2026 and December 31, 2025 | (25,000) | (25,000) | |||||||||
| Total stockholders’ equity | 177,106 | 152,746 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,091,441 | $ | 1,020,042 | |||||||
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Revenue, net | $ | 221,592 | $ | 192,884 | $ | 645,154 | $ | 538,248 | ||||||||||||||||||
| Cost of revenue | 57,098 | 55,762 | 176,102 | 159,053 | ||||||||||||||||||||||
| Gross profit | 164,494 | 137,122 | 469,052 | 379,195 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Research and development | 20,599 | 21,033 | 61,800 | 63,564 | ||||||||||||||||||||||
| Acquired in-process research and development | 303 | 302 | 898 | 2,296 | ||||||||||||||||||||||
| Selling, general and administrative | 125,636 | 124,216 | 393,175 | 370,549 | ||||||||||||||||||||||
| Litigation settlements | 49,788 | — | 63,738 | — | ||||||||||||||||||||||
| Impairment charges | 723 | — | 723 | 2,479 | ||||||||||||||||||||||
| Total operating expenses | 197,049 | 145,551 | 520,334 | 438,888 | ||||||||||||||||||||||
| Loss from operations | (32,555) | (8,429) | (51,282) | (59,693) | ||||||||||||||||||||||
| Interest and other income, net: | ||||||||||||||||||||||||||
| Interest income | 4,699 | 5,944 | 14,354 | 16,184 | ||||||||||||||||||||||
| Interest expense | (3,298) | (3,281) | (9,882) | (9,832) | ||||||||||||||||||||||
| Other income, net | 1,303 | 578 | 3,145 | 3,717 | ||||||||||||||||||||||
| Total interest and other income, net | 2,704 | 3,241 | 7,617 | 10,069 | ||||||||||||||||||||||
| Loss before income taxes | (29,851) | (5,188) | (43,665) | (49,624) | ||||||||||||||||||||||
| Income tax provision | — | 24 | 500 | 506 | ||||||||||||||||||||||
| Net loss | $ | (29,851) | $ | (5,212) | $ | (44,165) | $ | (50,130) | ||||||||||||||||||
| Net loss per common share, basic and diluted | $ | (0.90) | $ | (0.16) | $ | (1.35) | $ | (1.57) | ||||||||||||||||||
| Weighted-average shares, basic and diluted | 33,099 | 32,170 | 32,836 | 31,919 | ||||||||||||||||||||||
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Adjusted EBITDA reconciliation* | ||||||||||||||||||||||||||
Net loss, as reported1 | $ | (29,851) | $ | (5,212) | $ | (44,165) | $ | (50,130) | ||||||||||||||||||
| Interest expense | 3,298 | 3,281 | 9,882 | 9,832 | ||||||||||||||||||||||
| Interest income | (4,699) | (5,944) | (14,354) | (16,184) | ||||||||||||||||||||||
| Changes in fair value of strategic investments | (832) | (894) | (3,101) | (3,889) | ||||||||||||||||||||||
| Income tax provision | — | 24 | 500 | 506 | ||||||||||||||||||||||
| Depreciation and amortization | 5,324 | 5,173 | 15,588 | 15,488 | ||||||||||||||||||||||
| Stock-based compensation | 19,490 | 21,006 | 61,020 | 67,177 | ||||||||||||||||||||||
| Impairment charges | 723 | — | 723 | 2,479 | ||||||||||||||||||||||
Business transformation costs2 | 6,590 | 913 | 8,094 | 2,341 | ||||||||||||||||||||||
Intellectual property litigation expenses3 | 1,211 | 3,212 | 9,828 | 7,000 | ||||||||||||||||||||||
Litigation settlements4 | 49,788 | — | 63,738 | — | ||||||||||||||||||||||
Cybersecurity incident5 | 142 | — | 828 | — | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 51,184 | $ | 21,559 | $ | 108,581 | $ | 34,620 | ||||||||||||||||||
| Adjusted net income (loss) reconciliation* | ||||||||||||||||||||||||||
Net loss, as reported1 | $ | (29,851) | $ | (5,212) | $ | (44,165) | $ | (50,130) | ||||||||||||||||||
| Impairment charges | 723 | — | 723 | 2,479 | ||||||||||||||||||||||
Business transformation costs2 | 6,590 | 913 | 8,094 | 2,341 | ||||||||||||||||||||||
Intellectual property litigation expenses3 | 1,211 | 3,212 | 9,828 | 7,000 | ||||||||||||||||||||||
| Changes in fair value of strategic investments | (832) | (894) | (3,101) | (3,889) | ||||||||||||||||||||||
Litigation settlements4 | 49,788 | — | 63,738 | — | ||||||||||||||||||||||
Cybersecurity incident5 | 142 | — | 828 | — | ||||||||||||||||||||||
Tax effect of adjustments6 | 44 | 5 | (153) | (300) | ||||||||||||||||||||||
| Adjusted net income (loss) | $ | 27,815 | $ | (1,976) | $ | 35,792 | $ | (42,499) | ||||||||||||||||||
| Interest expense on senior convertible notes, net of tax | $ | 3,298 | $ | — | $ | — | $ | — | ||||||||||||||||||
| Numerator used in computing adjusted net income (loss) per diluted share | $ | 31,113 | $ | (1,976) | $ | 35,792 | $ | (42,499) | ||||||||||||||||||
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Financial Information (continued)
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Adjusted net income (loss) per diluted share reconciliation* | ||||||||||||||||||||||||||
Net loss, as reported1 | $ | (0.90) | $ | (0.16) | $ | (1.35) | $ | (1.57) | ||||||||||||||||||
| Impairment charges | 0.02 | — | 0.02 | 0.08 | ||||||||||||||||||||||
Business transformation costs2 | 0.17 | 0.03 | 0.24 | 0.07 | ||||||||||||||||||||||
Intellectual property litigation expenses3 | 0.03 | 0.10 | 0.29 | 0.22 | ||||||||||||||||||||||
| Changes in fair value of strategic investments | (0.02) | (0.03) | (0.09) | (0.12) | ||||||||||||||||||||||
Litigation settlements4 | 1.31 | — | 1.90 | — | ||||||||||||||||||||||
Cybersecurity incident5 | — | — | 0.02 | — | ||||||||||||||||||||||
Tax effect of adjustments6 | — | — | — | (0.01) | ||||||||||||||||||||||
| Interest expense on senior convertible notes, net of tax | 0.09 | — | — | — | ||||||||||||||||||||||
Impact of adjustment to diluted shares, as reported7 | 0.12 | — | 0.04 | — | ||||||||||||||||||||||
| Adjusted net income (loss) per diluted share | $ | 0.82 | $ | (0.06) | $ | 1.07 | $ | (1.33) | ||||||||||||||||||
| Weighted-average shares, basic and diluted, as reported | 33,099 | 32,170 | 32,836 | 31,919 | ||||||||||||||||||||||
| Equity incentive awards | 337 | — | 634 | — | ||||||||||||||||||||||
| Senior convertible notes | 4,492 | — | — | — | ||||||||||||||||||||||
| Weighted-average shares used in computing adjusted net income (loss) per diluted share | 37,928 | 32,170 | 33,470 | 31,919 | ||||||||||||||||||||||
| Adjusted operating expenses reconciliation* | ||||||||||||||||||||||||||
| Operating expenses, as reported | $ | 197,049 | $ | 145,551 | $ | 520,334 | $ | 438,888 | ||||||||||||||||||
| Impairment charges | (723) | — | (723) | (2,479) | ||||||||||||||||||||||
Business transformation costs2 | (6,590) | (913) | (8,094) | (2,341) | ||||||||||||||||||||||
Intellectual property litigation expenses3 | (1,211) | (3,212) | (9,828) | (7,000) | ||||||||||||||||||||||
Litigation settlements4 | (49,788) | — | (63,738) | — | ||||||||||||||||||||||
Cybersecurity incident5 | (142) | — | (828) | — | ||||||||||||||||||||||
| Adjusted operating expenses | $ | 138,595 | $ | 141,426 | $ | 437,123 | $ | 427,068 | ||||||||||||||||||
| Free cash flow reconciliation* | ||||||||||||||||||||||||||
Net cash provided by operating activities8 | $ | 4,438 | $ | 34,883 | $ | 29,345 | $ | 54,651 | ||||||||||||||||||
| Less: Purchases of property and equipment | (15,983) | (14,831) | (36,453) | (34,619) | ||||||||||||||||||||||
| Free cash flow | $ | (11,545) | $ | 20,052 | $ | (7,108) | $ | 20,032 | ||||||||||||||||||
*Certain numbers expressed may not sum due to rounding.
1 Net loss for the three and nine months ended September 30, 2026 includes $0.3 million and $0.9 million of acquired in-process research and development expense, and $0.3 million and $2.3 million for the three and nine months ended September 30, 2025, respectively.
2 Business transformation costs include $6.0 million associated with the VitalConnect acquisition for the three and nine months ended September 30, 2026.
3 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.
4 Excludes charges for Baxter patent litigation and securities class action litigation settlement, net of expected insurance recoveries.
5 Represents expenses directly related to the Cybersecurity Incident, net of expected insurance recoveries, including investigation and remediation, customer notifications, and professional and consultancy expenses.
6 Income tax impact of Non-GAAP adjustments listed.
7 The adjustments are for the transition from net loss per diluted share, as reported, to adjusted net income per diluted share, due to our dilutive securities, which include equity incentive awards and senior convertible notes.
8 Net cash provided by operating activities for the three and nine months ended September 30, 2026 includes $50.0 million of Baxter patent litigation settlement costs.